BioSpace News Archive

Alpine Immune Sciences, Inc., a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced that the Company will participate in two upcoming healthcare conferences.

Devonian Health Group Inc. announced that it has entered into a twelve month term loan in a principal of $2,160,000 from Fiera Private Debt Inc., following the repayment of its $3,500,000 long term loan, which matured January 17, 2024.

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) today announced that members of its management team are scheduled to participate in the 45th Annual Raymond James Institutional Investor Conference on March 5, 2024, in Orlando, FL.

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2023 on Monday, March 4, 2024, after the close of U.S.-based financial markets.

Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) approved Kezar’s investigational new drug (IND) application for initiation of the Phase 2b PALIZADE trial in China of zetomipzomib in patients with lupus nephritis (LN).

Bitterroot Bio, a leader in innovative treatments for cardiovascular diseases, and Biotheus, a pioneer in monoclonal and multi-specific antibody design, announced a multi-year research collaboration agreement.

Quanterix Corporation (NASDAQ: QTRX) today announced that it has rescheduled the release of its financial results for the fourth quarter and year ended December 31, 2023 and the associated conference call in order to more closely align the release of such results with the filing of its Annual Report on Form 10-K for the year ended December 31, 2023, the deadline for which is February 29, 2024.

Intellipharmaceutics International Inc. announced that its annual audited financial statements for the fiscal year ended November 30, 2023, related management’s discussion and analysis and accompanying Chief Executive Officer and Chief Financial Officer certificates and annual information form for the fiscal year ended November 30, 2023 due February 28, 2024 will not be filed by the Filing Deadline.

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to cutting-edge technology innovations and providing a total solution from “Idea to IND”, announced that it has entered into a collaboration agreement with Boostimmune, a biotech company dedicated to developing next-generation anti-cancer therapies via modulating immune systems.

Takeda and Biological E. Limited, a leading India-based Vaccines and Pharmaceutical Company, announced a strategic partnership to accelerate access to QDENGA®▼ multi-dose vials.